Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Daniel Feiler (NPI 1245572916)

Field	Value
Entity Type	Individual
Organization	Daniel Feiler
Address	8600 Quivira Rd Ste 100
City	Lenexa
State	KS
ZIP	66215
Taxonomy	Ophthalmology Physician
NPI Enumerated	March 20, 2013

Payer Source	Total Paid
Medicare	$4.8M
Medicaid	$0

Key Findings

DANIEL FEILER is an ophthalmology physician in Lenexa, KS with lifetime Medicare revenue of $4.8M and no Medicaid billing on file; the absence of any Medicaid claims indicates this practice is effectively single‑payer (Medicare) in the available billing data and will be highly sensitive to Medicare reimbursement and utilization dynamics. The NPI was enumerated 2013-03-20 (~13 years ago), indicating an established practice presence during the sampled period.

Revenue is highly concentrated in a small set of drug and procedure codes: the precomputed top 3 Medicare codes by revenue account for 86.4% of this provider's total Medicare revenue, with J0178 alone representing $3.5M (73.9% of Medicare revenue). This degree of concentration signals that a single drug product (aflibercept) is the dominant revenue driver for this provider.

The CPT/HCPCS mix shows a retina- and injection-focused practice model: very high volumes for intravitreal drug codes (J0178: 5.1K claims; J2777: 12.7K claims; J7312: 721 claims; J2778: 585 claims) alongside frequent retinal imaging (92134: 3.5K claims) and injection procedure coding (67028: 2.6K claims). This pattern is consistent with a practice that delivers regular anti-VEGF and implant therapies supported by diagnostic OCT and fundus imaging.

On competitive standing, this provider is a national high-volume injector for aflibercept: J0178 ranks #24 of 3204 providers nationally (99th percentile; extreme outlier), placing the provider well above typical national volume for that code. In contrast, J2777 (faricimab) ranks #832 of 2039 (59th percentile; typical) which suggests dominance is concentrated on aflibercept rather than across all newer biologic agents.

Several other codes also show above-typical or outlier volumes that reinforce a retinal specialty orientation: 92134 ranks #231 of 26868 providers nationally (99th percentile; extreme outlier) for retinal OCT imaging, 67028 ranks #157 of 4255 (96th percentile; notably above typical) for intravitreal injection as an isolated procedure, and J7312 (dexamethasone implant) ranks #11 of 492 (98th percentile; notably above typical). These rank/percentile placements indicate the provider is a prominent local/national performer on multiple retina-specific services, not only one-off billing spikes.

Operational scale and throughput are evident in claim counts as well as revenue: 5.1K J0178 claims and 3.5K 92134 claims reflect sustained, high-frequency service delivery rather than isolated episodes of care. That sustained procedural throughput implies the practice requires consistent staffing, injection suite capacity, and imaging resources to support ongoing treatment regimens.

Because most revenue is driven by high-cost injectables and implants (notably J0178 at $688 avg paid/claim and J7312 at $159 avg paid/claim) the provider’s financial performance is concentrated in drug reimbursement and utilization patterns; changes in drug pricing, coverage policies, or utilization management for these agents would likely have outsized effects on revenue. The operational profile (heavy injection and imaging volumes) also creates exposure to clinical practice guideline changes that affect treatment frequency.

The lack of any Medicaid billing ("none below") combined with the Medicare-dominated revenue picture indicates a payer mix skewed away from Medicaid patients; this will affect negotiations, access programs, and potential revenue diversification strategies. Analysts should treat this provider as primarily Medicare-facing when benchmarking payer performance or considering network adequacy for Medicaid populations.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

19 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	5,130	$690	$3.5M
J2777	Injection, faricimab‑svoa, 0.1 mg	12,660	$30	$367.1K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	2,580	$90	$226.8K
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg	720	$160	$114.6K
J2778	Injection, ranibizumab, 0.1 mg	590	$180	$105.9K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	1,150	$80	$92.3K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	3,480	$20	$83.4K
J3490	Unclassified drugs	30	$1,810	$59.6K
92235	The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken…	300	$100	$29.2K
J3590	Unclassified biologics	160	$170	$26.8K

Showing 1–10 of 19

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Daniel Feiler — 7 of 19 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

19 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	2	30	1,770	$690	$1.3M
J2777	12	30	12,060	$30	$575.7K
J2778	16	20	860	$180	$297.6K
67028	3	40	1,170	$90	$111.4K
J7312	1	10	260	$160	$43.6K
67042	7	20	20	$1,140	$31.9K
67108	16	20	20	$1,130	$24.8K
J3590	12	20	200	$100	$24.1K
J3490	18	20	120	$200	$23.4K
92014	4	530	180	$70	$18.5K

Showing 1–10 of 19

Related Providers

Other providers that share a Tax Identification Number (TIN) with Daniel Feiler, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Thomas Finley	OK	Ophthalmology Physician	$4.8M	$0
Travis Koeneke	KS	Hematology & Oncology Physician	$4.4M	$0
Christopher Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Stephen Wiles	MO	Ophthalmology Physician	$4.4M	$0
Shaker Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Justin Gooden	KS	Undersea and Hyperbaric Medicine (Preventive Medicine) Physician	$4.3M	$0

Nearby Providers

Other providers in the same ZIP code as Daniel Feiler, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bethesda Lutheran Communities	KS	Mental Illness Intermediate Care Facility	$0	$17.6M
Cherub Medical Supply, LLC	KS	Durable Medical Equipment & Medical Supplies	$0	$6.3M
Mawd Pathology Group Inc	KS	Anatomic Pathology & Clinical Pathology Physician	$660	$5.9M
Gregory Fox	KS	Ophthalmology Physician	$4M	$0
Ravi Singh	KS	Ophthalmology Physician	$3.9M	$0
Cpf Senior Living - Lenexa LLC	KS	Assisted Living Facility	$0	$3.8M
Beatty Suiter	KS	Ophthalmology Physician	$3.5M	$0
Ryan Christensen	KS	Ophthalmology Physician	$3.3M	$0
180 Medical, Inc.	KS	Durable Medical Equipment & Medical Supplies	$0	$2.7M
Midwest Division-oprmc LLC	KS	General Acute Care Hospital	$0	$2.6M

Daniel Feiler — Billing Profile & Reimbursement Data

Sign up for Daniel Feiler — Billing Profile & Reimbursement Data policy alerts

Daniel Feiler — Billing Profile & Reimbursement Data

Sign up for Daniel Feiler — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References